Tel: 732-484-9848
Fax: 888-484-5008
Email: sales@chemscene.com
   
Buliding blocks
Intermediates
Bioactive molecules
Product Pathways
All Targets
Anti-infection
Antibody-drug conjugate....
Apoptosis
Biochemical Reagent
Cell Cycle/DNA Damage
GPCR/G protein
Immunology/Inflammation
JAK/STAT Signaling
MAPK/ERK Pathway
Membrane Transporter/Io....
Metabolism/Protease
Microbiology
Neuronal Signaling
NF-KB
Others
PI3K/Akt/mTOR
Protein Tyrosine Kinase....
TGF-beta/Smad
Vitamin D Related
Wnt/Hedgehog/Notch
Research Area
Cancer
Cardiovascular Disease
Endocrinology
Infection
Metabolic Disease
Neurological Disease
Others
Inflammation/Immunology
Product Type
All Products
New Products
Featured Products
Home   »   Product Pathways  »  Cancer  »  AS703026

Products are for research use only. Not for human use. We do not sell to patients.


CS-0198 AS703026


(MSC1936369B;AS-703026;AS 703026)
Structure Price and Availability of    AS703026
United States
Size Price Stock
5mg $40 In-stock Inquiry
1g Get quote
5g Get quote
>10g Get quote
 Distributor In Japan:  フナコシ株式会社 www.funakoshi.co.jp    
電話番号:81-3-5684-1620    FAX番号:81-3-5684-1775
Inquiry for price and availability only. Please place your order via our email or fax.
Contact us for competitive discounts on bulk quantities .
  • Data Sheet
  • Introduction
  • References
  • Related Products

AS703026  M.Wt: 431.2
AS703026  Formula: C15H15FIN3O3
AS703026  Solubility: DMSO ≥83mg/mL Water <1.2mg/mL Ethanol ≥2.6mg/mL
AS703026  Purity: >98%
AS703026  Storage:  Please store the product under the recommended conditions in the Certificate of Analysis.
CAS: 1236699-92-5

View current batch:

AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor (cell IC50 ranging from 0.005 to 2 μM).

1 . Daver N, Cortes J.Molecular targeted therapy in acute myeloid leukemia.Hematology. 2012 Apr;17 Suppl 1:S59-62.
Abstract
The treatment of acute myeloid leukemia has not changed significantly over the last 40 years. Recent progress in understanding the biology of this disease and identification of driver mutations has ushered in a new era of molecular therapeutics. Although a number of molecular markers and pathways have been identified and may serve as potential therapeutic targets, the best studied amongst these include FMS like tyrosine kinase 3 (FLT3), RAS/RAF/MEK/ERK and Janus kinase (JAK-2). In this review we discuss the molecular biology of AML, with a special focus on the above mentioned pathways. We discuss novel molecular targeted therapies that are in preclinical and clinical development. These include AC-220, sorafenib and midostaurin in FLT3 mutated patients; GSK1120212 and MSC1936369B in RAS mutated patients; and INCB018424 in JAK2 mutated patients. Identification of such molecular mutations and appropriate use of targeted therapies, either alone or in combinations, may eventually revolutionize the treatment of AML.

2 . Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.Br J Haematol. 2010 May;149(4):537-49. Epub 2010 Mar 12.
Abstract
This study investigated the cytotoxicity and mechanism of action of AS703026, a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM). AS703026 inhibited growth and survival of MM cells and cytokine-induced osteoclast differentiation more potently (9- to 10-fold) than AZD6244. Inhibition of proliferation induced by AS703026 was mediated by G0-G1 cell cycle arrest and was accompanied by reduction of MAF oncogene expression. AS703026 further induced apoptosis via caspase 3 and Poly ADP ribose polymerase (PARP) cleavage in MM cells, both in the presence or absence of bone marrow stromal cells (BMSCs). Importantly, AS703026 sensitized MM cells to a broad spectrum of conventional (dexamethasone, melphalan), novel or emerging (lenalidomide, perifosine, bortezomib, rapamycin) anti-MM therapies. Significant tumour growth reduction in AS703026- vs. vehicle-treated mice bearing H929 MM xenograft tumours correlated with downregulated pERK1/2, induced PARP cleavage, and decreased microvessels in vivo. Moreover, AS703026 (<200 nmol/l) was cytotoxic against the majority of tumour cells tested from patients with relapsed and refractory MM (84%), regardless of mutational status of RAS and BRAF genes. Importantly, BMSC-induced viability of MM patient cells was similarly blocked within the same dose range. Our results therefore support clinical evaluation of AS703026, alone or in combination with other anti-MM agents, to improve patient outcome.

3 . Yoon J, Koo KH, Choi KY.MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.Cancer Res. 2011 Jan 15;71(2):445-53. Epub 2010 Nov 30.
Abstract
Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) are used widely to treat metastatic colorectal cancer (mCRC) patients, but it is now clear that patients harboring K-ras mutation are resistant to EGFR mAbs such as cetuximab (Erbitux) and panitumumab (Vectibix). For this reason, current recommendations for patient care involve diagnosing the K-ras mutational status of patients prior to EGFR mAb therapy. In this study, we investigated the ability of two MEK inhibitors currently in clinical trials, AS703026 and AZD6244, to address the challenge posed by the resistance of K-ras mutated colorectal cancers to EGFR mAb. AS703026 and AZD6244 were tested in various cell-based assays and tumor xenograft studies, focusing on isogenic human colorectal tumor cell lines that expressed only WT or mutant K-Ras (D-WT or D-MUT). The EGFR mAb cetuximab inhibited the Ras-ERK pathway and proliferation of D-WT cells in vitro and in vivo, but it did not inhibit proliferation of D-MUT cells in either setting. In contrast, AS703026 and AZD6244 effectively inhibited the growth of D-MUT cells in vitro and in vivo by specific inhibition of the key MEK downstream target kinase ERK. Inhibition of MEK by AS703026 or AZD6244 also suppressed cetuximab-resistant colorectal cancer cells attributed to K-ras mutation both in vitro and in vivo. Our findings offer proof-of-concept for the use of MEK inhibitors as an effective therapy in K-ras mutated CRC.

4 . Kim K et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May;149(4):537-49.
Abstract
Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) are used widely to treat metastatic colorectal cancer (mCRC) patients, but it is now clear that patients harboring K-ras mutation are resistant to EGFR mAbs such as cetuximab (Erbitux) and panitumumab (Vectibix). For this reason, current recommendations for patient care involve diagnosing the K-ras mutational status of patients prior to EGFR mAb therapy. In this study, we investigated the ability of two MEK inhibitors currently in clinical trials, AS703026 and AZD6244, to address the challenge posed by the resistance of K-ras mutated colorectal cancers to EGFR mAb. AS703026 and AZD6244 were tested in various cell-based assays and tumor xenograft studies, focusing on isogenic human colorectal tumor cell lines that expressed only WT or mutant K-Ras (D-WT or D-MUT). ...

MEK  |  
Keywords: buy AS703026 | AS703026 Supplier | purchase AS703026 | AS703026 cost | AS703026 manufacturer | order AS703026 | AS703026 distributor | AS703026 structure,chemscene
buy 1236699-92-5 | 1236699-92-5 Supplier | purchase 1236699-92-5 | 1236699-92-5 cost | 1236699-92-5 manufacturer | order 1236699-92-5 | 1236699-92-5 distributor | 1236699-92-5 structure,chemscene


CHEMSCENE, LLC
Tel: 732-484-9848
Fax: 888-484-5008
Email:  sales@chemscene.com
Address: 11 Deer Park Drive, Suite 102D Monmouth Junction, NJ 08852.
Products are for research use only. Not for human use. We do not sell to patients. Sitemap | Inhibitor © Copyright 2012. All Rights Reserved.